Kaczmarek Frank S, Gootz Thomas D, Dib-Hajj Fadia, Shang Wenchi, Hallowell Shawn, Cronan Melissa
Department of Immunology and Infectious Disease, Pfizer Global Research and Development, Groton, Connecticut 06340, USA.
Antimicrob Agents Chemother. 2004 May;48(5):1630-9. doi: 10.1128/AAC.48.5.1630-1639.2004.
Previous studies with beta-lactamase-negative, ampicillin-resistant (BLNAR) Haemophilus influenzae from Japan, France, and North America indicate that mutations in ftsI encoding PBP3 confer ampicillin MICs of 1 to 4 micro g/ml. Several BLNAR strains with ampicillin MICs of 4 to 16 micro g/ml recently isolated from North America were studied. Pulsed-field gel electrophoresis identified 12 unique BLNAR strains; sequencing of their ftsI transpeptidase domains identified 1 group I and 11 group II mutants, as designated previously (K. Ubukata, Y. Shibasaki, K. Yamamoto, N. Chiba, K. Hasegawa, Y. Takeuchi, K. Sunakawa, M. Inoue, and M. Konno, Antimicrob. Agents Chemother. 45:1693-1699, 2001). Geometric mean ampicillin MICs for several clinical isolates were 8 to 10.56 micro g/ml. Replacement of the ftsI gene in H. influenzae Rd with the intact ftsI from several clinical isolates resulted in integrants with typical BLNAR geometric mean ampicillin MICs of 1.7 to 2.2 micro g/ml. Cloning and purification of His-tagged PBP3 from three clinical BLNAR strains showed significantly reduced Bocillin binding compared to that of PBP3 from strain Rd. Based on these data, changes in PBP3 alone could not account for the high ampicillin MICs observed for these BLNAR isolates. In an effort to determine the presence of additional mechanism(s) of ampicillin resistance, sequencing of the transpeptidase regions of pbp1a, -1b, and -2 was performed. While numerous changes were observed compared to the sequences from Rd, no consistent pattern correlating with high-level ampicillin resistance was apparent. Additional analysis of the resistant BLNAR strains revealed frame shift insertions in acrR for all four high-level, ampicillin-resistant isolates. acrR was intact for all eight low-level ampicillin-resistant and four ampicillin-susceptible strains tested. A knockout of acrB made in one clinical isolate (initial mean ampicillin MIC of 10.3 micro g/ml) lowered the ampicillin MIC to 3.67 micro g/ml, typical for BLNAR strains. These studies illustrate that BLNAR strains with high ampicillin MICs exist that have combined resistance mechanisms in PBP3 and in the AcrAB efflux pump.
先前对来自日本、法国和北美的β-内酰胺酶阴性、氨苄西林耐药(BLNAR)流感嗜血杆菌的研究表明,编码PBP3的ftsI基因突变会使氨苄西林的最低抑菌浓度(MIC)达到1至4微克/毫升。最近对从北美分离出的几种氨苄西林MIC为4至16微克/毫升的BLNAR菌株进行了研究。脉冲场凝胶电泳鉴定出12种独特的BLNAR菌株;对其ftsI转肽酶结构域进行测序,鉴定出1个I组突变体和11个II组突变体,如先前所命名(K. Ubukata、Y. Shibasaki、K. Yamamoto、N. Chiba、K. Hasegawa、Y. Takeuchi、K. Sunakawa、M. Inoue和M. Konno,《抗菌药物与化疗》45:第1693 - 1699页,2001年)。几种临床分离株的氨苄西林MIC几何平均值为8至10.56微克/毫升。用几种临床分离株的完整ftsI基因替换流感嗜血杆菌Rd中的ftsI基因,得到的整合体具有典型的BLNAR氨苄西林MIC几何平均值,为1.7至2.2微克/毫升。从三种临床BLNAR菌株中克隆并纯化His标签的PBP3,结果显示与Rd菌株的PBP3相比,Bocillin结合显著减少。基于这些数据,仅PBP3的变化无法解释这些BLNAR分离株中观察到的高氨苄西林MIC。为了确定是否存在其他氨苄西林耐药机制,对pbp1a、-1b和-2的转肽酶区域进行了测序。虽然与Rd菌株的序列相比观察到许多变化,但没有明显的与高水平氨苄西林耐药相关联的一致模式。对耐药BLNAR菌株的进一步分析显示,所有四种高水平氨苄西林耐药分离株的acrR中存在移码插入。在测试的所有八种低水平氨苄西林耐药菌株和四种氨苄西林敏感菌株中,acrR都是完整的。在一种临床分离株(初始氨苄西林MIC平均值为10.3微克/毫升)中敲除acrB后,氨苄西林MIC降至3.67微克/毫升,这是BLNAR菌株的典型值。这些研究表明,存在具有PBP3和AcrAB外排泵联合耐药机制的高氨苄西林MIC的BLNAR菌株。